Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
6
×
boston top stories
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
6
×
biotech
deals
boston
new york blog main
new york top stories
san francisco
startups
dna
medical devices
roche
san diego blog main
san diego top stories
seattle blog main
seattle top stories
vc
accelerator
acetylon pharmaceuticals
agios therapeutics
airbnb
amazon web services (aws)
ambys medicines
artificial intelligence (a.i.)
athelas
atomwise
azacitidine
base editing
benchling
beta-thalassemia
biobucks
biofourmis
biotechnology
biovotion
branden moriarty
What
startup
6
×
therapeutics
big
biotech
medicines
million
new
sciences
adding
admits
ago
aiming
aims
ambys
analytics
approach
based
beam
bets
biofourmis
biotechs
boost
called
cancer
cas
classes
combinator
companies
control
crispr
data
deadly
deal
debuted
debuts
developing
devices
digital
diseases
drug
Language
unset
Current search:
startup
×
" boston blog main "
×
" san francisco top stories "
×
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
To Boost Cancer Pipeline, Gilead Bets at Least $50M on Startup Tango
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
6 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M